Protection of Cells from Degeneration and Treatment of Geographic Atrophy

A method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject an inhibitor of MyD88, wherein the disease or disorder is selected from macular degeneration;

• acne vulgaris;
• acquired immunodeficiency syndrome;
• acute tubular injury;
• allergic asthma;
• Alzheimer's disease;
• angiogenesis;
• atherosclerosis;
• acute bone marrow transplant rejection;
• chronic bone marrow transplant rejection;
• Burkholderia cenocepacia infection;
• chronic infantile neurological cutaneous and articular autoinflammatory diseases;
• chronic obstructive pulmonary disease;
• contact dermatitis;
• Crohn's disease;
• cryoglobulinemia;
• cryopyrinopathies;
• cystic fibrosis;
• drug-induced lung inflammation;
• familial cold autoinflammatory syndrome;
• geographic atrophy;
• glomerulonephritis;
• gout;
• hay fever;
• helminth parasite infection;
• hemolytic-uremic syndrome;
• human immunodeficiency virus;
• immune complex renal disease;
• IgA nephropathy;
• inflammatory bowel disease;
• inflammation associated with cardiac surgery;
• inflammatory joint disease;
• insulin resistance;
• irritable bowel syndrome;
• keratitis;
• leprosy;
• lupus nephritis;
• malaria;
• Muckle-Wells syndrome;
• neonatal onset multisystem inflammatory disease;
• non-alcoholic fatty liver disease;
• polyoma virus infection;
• obesity;
• acute organ transplant rejection;
• chronic organ transplant rejection;
• psoriasis;
• reactive arthritis;
• renal ischemia-perfusion injury;
• respiratory syncitial virus infection;
• retinal degeneration;
• rheumatoid arthritis;
• scleroderma;
• sepsis;
• septic shock;
• Sjögren's syndrome;
• syphilis;
• systemic lupus erythematosus;
• systemic vasculitides;
• tumor angiogenesis;
• type I diabetes;
• type 2 diabetes;
• and ulcerative colitis.